UroGen Pharma Ltd. - Ordinary Shares (URGN) earnings
URGN earnings moved a median of +1.54% by the close. Quarterly and annual URGN reports and results, each read against the price at its own news timestamp. Back to the URGN overview →
27 measured URGN earnings events.
Where these URGN earnings landedvs 26 measured URGN earnings reactions
| Middle 50% of URGN earnings reactions | -3.57% to +10.10% |
|---|---|
| Median reaction (to close) | +1.54% |
| Measured reactions | 26 |
Point-in-time · zero look-ahead
Half of the 26 URGN earnings events with a measured close landed between -3.57% and +10.10%; 58% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q UroGen Pharma Ltd. For: Jun 30 | SEC filing · Form 10-Q | +2.10% | +10.10% | |
| UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights | Press release | +2.10% | +10.10% | |
| UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026 | Press release | +0.05% | -1.58% | |
| Form 10-Q UroGen Pharma Ltd. For: Mar 31 | SEC filing · Form 10-Q | +2.15% | +4.08% | |
| UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights | Press release | +2.15% | +4.08% | |
| UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026 | Press release | +0.08% | -2.79% | |
| Form 10-K UroGen Pharma Ltd. For: Dec 31 | SEC filing · Form 10-K | -8.31% | -12.19% | |
| Form 10-Q UroGen Pharma Ltd. For: Sep 30 | SEC filing · Form 10-Q | +2.98% | +28.77% | |
| UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum | Press release | +2.98% | +28.77% | |
| UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025 | Press release | -0.81% | +0.61% | |
| Form 10-Q UroGen Pharma Ltd. For: Jun 30 | SEC filing · Form 10-Q | -3.00% | -3.83% | |
| UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results | Press release | -3.00% | -3.83% | |
| UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 | Press release | +0.00% | — | |
| Form 10-Q UroGen Pharma Ltd. For: Mar 31 | SEC filing · Form 10-Q | +3.43% | +14.14% | |
| UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update | Press release | +3.43% | +14.14% | |
| UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 | Press release | +0.52% | +0.17% | |
| Form 10-K/A UroGen Pharma Ltd. For: Dec 31 | SEC filing · Form 10-K | -0.78% | -1.04% | |
| Form 10-K UroGen Pharma Ltd. For: Dec 31 | SEC filing · Form 10-K | -0.46% | +10.75% | |
| Form 10-Q UroGen Pharma Ltd. For: Sep 30 | SEC filing · Form 10-Q | -4.45% | -7.62% | |
| Form 10-Q UroGen Pharma Ltd. For: Jun 30 | SEC filing · Form 10-Q | +1.48% | +5.50% | |
| UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024 | Press release | +0.14% | +4.72% | |
| Form 10-Q UroGen Pharma Ltd. For: Mar 31 | SEC filing · Form 10-Q | +9.82% | +19.91% | |
| Form 10-K/A UroGen Pharma Ltd. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -1.27% | |
| Form 10-K UroGen Pharma Ltd. For: Dec 31 | SEC filing · Form 10-K | -0.27% | -14.55% | |
| Form 10-Q UroGen Pharma Ltd. For: Sep 30 | SEC filing · Form 10-Q | -3.78% | -4.03% | |
| UroGen Pharma Reports Third Quarter 2023 Financial Results | Press release | -3.78% | -4.03% | |
| UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023 | Press release | +0.26% | +2.47% |
Keep exploring
More URGN: analyst actions → · SEC filings → · URGN overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| PolarityTE, Inc. (PTE) | 670 | -0.62% | 38% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 664 | -0.07% | 48% |
| Brainstorm Cell Therapeutics Inc. (BCLI) | 660 | 0.00% | 47% |
| OPHTHOTECH CORP COMMON (OPHT) | 660 | -0.20% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.